Clark exits Merck Dec. 1, passing chairman title to CEO

Merck ($MRK) Chairman Richard Clark (photo) will retire Dec. 1, leaving Kenneth Frazier (photo) with the dual role of chairman and CEO. Frazier took the operational reins at Merck in January after the company's mandatory retirement age forced Clark to step down. Report | Item

Suggested Articles

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.